Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

Renal Failure

Volumn 38, Issue 10, 2016, Pages 1601-1606

  Samouilidou, Elisabeth ^a   Kostopoulos, Vassilis ^a   Liaouri, Augustina ^a   Kioussi, Eva ^b   Vassiliou, Kyriaki ^c   Bountou, Eirini ^b   Grapsa, Eirini ^b  

^a ALEXANDRA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

HDL C subclasses; hemodialysis; paraoxonase 1 concentration

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; GREECE; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84959038416     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2016.1144031     Document Type: Article

References (27)

1. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Pamo SL, La Du BN., Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581–1590.
2. Kaysen G., Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73–77.
3. Rosenblat M, Volkova N, Ward I, Aviram M., Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation. Atherosclerosis. 2011;219:49–56.
4. Gugliucci A, Kotani K, Kimura S., Paraoxonase 1 in chronic kidney failure. J Lipids. 2012;2012:726048.
5. Mackness M, Mackness B, Durringrton PN., Paraoxonase and coronary heart disease. Atherosclerosis Suppl. 2002;3:49–55.
6. Precourt LP, Amre D, Deni MC, Lavoie JC, Delvib E, Seldman E., The three-gene paraoxonase family:Physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.
7. Schiavon R, Battaglia P, De Fanti E, et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients:Comparison with the PON1 allele polymorphism. Clin Chim Acta. 2002;324:39–44.
8. Kontush A, Chantepie S, Chapman MJ., Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Ather Thromb Vasc Biol. 2003;23:1881–1888.
9. Lewis D, Haynes R, Landray M., Lipids in chronic kidney disease. J Ren Care. 2010;36:27–33.
10. Vaziri N, Navab M, Fogelman AM., HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6:287–296.
11. Samouilidou E, Karpouza A, Grapsa E, Tzanatou-Exarchou H., Serum oxidized LDL is inversely associated with HDL2-cholesterol subclass in renal failure patients on hemodialysis. Nephron Clin Pract. 2010;115:c289–c294.
12. Kennedy D, Tang W, Fan Y, Wu Y, Mann S, Pepoy BS., Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc. 2013;2:e000104. doi:1161/JAHA.112.000104.
13. Johnson-Davis K, Fernalius C, Eliason N, Wilson A, Beddhu S, Roberts W., Blood enzymes and oxidative stress in chronic kidney disease:A cross sectional study. Ann Clin Lab Sci. 2011;41:331–339.
14. Kotur-Stevuljevic J, Peco-Antic A, Spasic S, et al. Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. Pediatr Nephr. 2013;28:295–303.
15. Ikeda Y, Suehiro T, Itahara T, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol. 2007;67:358–365.
16. Harangi M, Seres I, Harangi J, Paragh G., Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment. Cardiovasc Drugs Ther. 2009;23:501–510.
17. Miyamoto-Sasaki M, Yasuda T, Mongushi T, et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Ather Thromb. 2013;20:708–716.
18. Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y., A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. J Lipid Res. 2008;49:1130–1136.
19. Puchades MJ, Saez G, Munez MC, et al. Study of oxidative stress in patients with advanced renal disease and undergoing either hemodialysis or peritoneal dialysis. Clin Nephrol. 2013;80:177–186.
20. Kimak E, Ksiazek A, Solski J., Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure. Clin Chem Lab Med. 2006;44:64–69.
21. Marsillach J, Martinez-Vea A, Mareas L, Mackness B, Mackness M, Ferré N., Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin Exp Pharmacol Physiol. 2007;34:347–349.
22. Suehiro T, Ikeda Y, Shiinoki T, et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb. 2002;9:133–138.
23. Gugliucci A, Kinusa E, Ogata H, Caccavello A, Kimura S., Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL. Clin Chim Acta. 2014;430:9–14.
24. Patra SK, Singh K, Singh R., Paraoxonase 1:a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus. Diabetes Metab Syndr. 2014;7:108–111.
25. Alabakova S, Todorova S, Labudovic D, Tosheska K., LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem. 2002;35:211–216.
26. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481–488.
27. Ribeiro S, do Sameiro Faria M, Mascarenhas-Melo F, et al. Main determinants of PON1 activity in hemodialysis patients. Am J Nephrol. 2012;36:317–323.